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Summary
Objective: The true prevalence of epileptic seizures and epilepsy in 22q11.2 deletion 
syndrome (22q11.2DS) is unknown, because previous studies have relied on histori-
cal medical record review. Associations of epilepsy with other neurodevelopmental 
manifestations (eg, specific psychiatric diagnoses) remain unexplored.
Methods: The primary caregivers of 108 deletion carriers (mean age 13.6 years) and 60 
control siblings (mean age 13.1 years) completed a validated epilepsy screening ques-
tionnaire. A subsample (n = 44) underwent a second assessment with interview, pro-
longed electroencephalography (EEG), and medical record and epileptologist review. 
Intelligence quotient (IQ), psychopathology, and other neurodevelopmental problems 
were examined using neurocognitive assessment and questionnaire/interview.
Results: Eleven percent (12/108) of deletion carriers had an epilepsy diagnosis (con-
trols 0%, P = 0.004). Fifty- seven of the remaining 96 deletion carriers (59.4%) had 
seizures or seizurelike symptoms (controls 13.3%, 8/60, P < 0.001). A febrile seizure 
was reported for 24.1% (26/107) of cases (controls 0%, P < 0.001). One deletion 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.
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1 |  INTRODUCTION
The most common recurrent microdeletion syndrome in hu-
mans is 22q11.2 deletion syndrome (22q11.2DS), which oc-
curs in ~1 in 2000- 4000 live births.1 In the majority of cases, 
a de novo 3 megabase (Mb) deletion occurs between low copy 
repeats (LCRs) 22A- 22D, causing the loss of 46 protein- coding 
genes.2 This deletion syndrome has a variable phenotype, with 
characteristic features including congenital heart disease, pal-
atal abnormalities, hypocalcemia, mild- moderate intellectual 
disability (ID), and psychiatric disorders such as schizophre-
nia, attention- deficit/hyperactivity disorder (ADHD), anxiety 
disorder and autism spectrum disorder (ASD).3–11
The deletion increases the risk of acute symptomatic and 
unprovoked epileptic seizures, although the reported rates 
are wide- ranging. Between 1% and 14.5% of patients have 
hypocalcemia- induced seizures.12–16 In adulthood, 17.6% 
of patients with 22q11.2DS exposed to psychotropic drugs 
have epileptic seizures, suggesting a reduced seizure thresh-
old.13 Between 4.4% and 36.8% have repeated unprovoked 
seizures (ie, epilepsy).9,13–15,17,18 Structural brain abnormali-
ties in these individuals can include diffuse cerebral atrophy 
(18.8%), polymicrogyria (13.9%), hippocampal malrotation 
(10.9%), gray and white matter heterotopia (5.9%), and focal 
cortical dysplasia (2%).19 Between 1% and 6.9% of patients 
have genetic generalized epilepsy (GGE),13–15,17 and the de-
letion prevalence is elevated in GGE cohorts.20
To date, studies investigating the prevalence of epilep-
tic seizures and epilepsy in deletion carriers have relied on 
retrospective medical record review. Such records are less 
suited to systematic evaluation, because of differences be-
tween clinicians in diagnostic methods and documentation. 
This approach may furthermore miss cases of nonconvulsive 
seizures (eg, absences) not seen clinically. Nonconvulsive 
carrier with a clinical history of epilepsy was diagnosed with an additional type of 
unprovoked seizure during the second assessment. One deletion carrier was newly 
diagnosed with epilepsy, and two more with possible nonmotor absence seizures. A 
positive screen on the epilepsy questionnaire was more likely in deletion carriers with 
lower performance IQ (odds ratio [OR] 0.96, P = 0.018), attention-deficit/hyperac-
tivity disorder (ADHD) (OR 3.28, P = 0.021), autism symptoms (OR 3.86, 
P = 0.004), and indicative motor coordination disorder (OR 4.56, P = 0.021).
Significance: Even when accounting for deletion carriers diagnosed with epilepsy, 
reports of seizures and seizurelike symptoms are common. These may be “true” epi-
leptic seizures in some cases, which are not recognized during routine clinical care. 
Febrile seizures were far more common in deletion carriers compared to known popu-
lation risk. A propensity for seizures in 22q11.2DS was associated with cognitive 
impairment, psychopathology, and motor coordination problems. Future research is 
required to determine whether this reflects common neurobiologic risk pathways or 
is a consequence of recurrent seizures.
K E Y W O R D S
electroencephalography, febrile seizure, psychiatric disorder, seizure semiology, unprovoked seizure
Key points
• Over half of young people with 22q11.2 deletion 
syndrome (22q11.2DS) without an epilepsy diag-
nosis were reported as having a seizure or seizure-
like symptom
• We conducted a second assessment stage in a sub-
sample of 44 people including an interview, a pro-
longed electroencephalography (EEG) assessment, 
and a medical record review
• This highlighted that in some deletion carriers, epi-
leptic seizures may not be recognized during routine 
clinical care and that epilepsy may be overlooked
• A quarter of young people with 22q11.2DS 
screened positive for febrile seizures, a higher rate 
than reported in previous studies in this population
• Epilepsy, seizures, and seizurelike symptoms 
were associated with attention-deficit/hyperactiv-
ity disorder (ADHD), autism spectrum disorder 
(ASD) symptoms, motor coordination problems, 
and a lower performance intelligence quotient 
(IQ) in 22q11.2DS
Thomas Charitable Fund (2315/1), and 
Health & Care Research Wales (Welsh 
Government, 507556).
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seizures normally occur several times before the affected in-
dividual and their family seek clinical advice.21 Andrade et al 
(2013) were the first to conduct a direct, systematic study 
of epilepsy in 22q11.2DS, including epileptologist, magnetic 
resonance imaging (MRI), and prolonged electroencepha-
lography (EEG) assessment. They observed that 36.8% of 
patients had epilepsy, although their sample consisted of 19 
adults only.18 Thus, previous research may have underesti-
mated the prevalence of epileptic seizures and epilepsy in 
22q11.2DS, particularly in young people. In addition, there 
is a dearth of research into salient seizure characteristics in 
22q11.2DS, such as length and frequency, increases in which 
associate with poorer neurodevelopmental outcomes in the 
general population.22,23
Studies based primarily on historical medical record re-
view have also assessed the relationships of epileptic seizures 
and epilepsy with cognitive and psychiatric development 
in 22q11.2DS. Neonatal seizures (mostly hypocalcemia- 
induced) predict poorer intellectual functioning later in life.16 
Epilepsy also associates with a higher rate of developmental 
delay, but not with psychiatric disorder.17 The relationships 
of epilepsy with specific psychiatric diagnoses (eg, ADHD) 
and other salient manifestations of 22q11.2DS, such as sleep 
disturbance24 and motor coordination problems,4 have not 
been explored.
Our study had three aims: First, we explored the rates of 
an epilepsy diagnosis, seizures, and seizurelike symptoms 
(behaviors that may reflect unrecognized epileptic seizures) 
in young people with 22q11.2DS and their unaffected con-
trol siblings, through data obtained from a validated ques-
tionnaire completed by the primary caregiver. To support 
these findings, we conducted a second stage of assessment 
with a subsample, involving primary caregiver interview, 
prolonged EEG assessment, and a medical record review. 
These data were then reviewed by an epileptologist, who 
made diagnoses of epileptic seizures and epilepsy.
Second, we sought to delineate salient seizure character-
istics in deletion carriers who took part in the second assess-
ment, such as etiology, semiology, age at onset, length, and 
frequency.
Third, we investigated whether epilepsy questionnaire re-
sponses were predicted by intellectual functioning (IQ and 
ID), psychopathology (ADHD, anxiety disorder, and indic-
ative ASD), motor coordination problems, and sleep distur-
bance in deletion carriers.
2 |  METHODS
2.1 | Participants
We recruited 108 deletion carriers (57.4% male, mean 
age 13.6 years, standard deviation [SD] 3.3, range 6.2- 20.5) and 
60 unaffected control siblings (50% male, mean age 13.1 years, 
SD 3.2, range 6.3- 18.9) via UK genetics clinics and charities 
for chromosomal conditions. The deletion was identified in 
the clinics (fluorescence in situ hybridization/microarray) and 
confirmed in the MRC Centre for Neuropsychiatric Genetics 
and Genomics laboratory (microarray). For 15.8% of cases, in-
formation about deletion size was not provided and we could 
not obtain a biologic sample for verification. In the remain-
der, the majority had the typical de novo ~3 megabase (Mb) 
A- D deletion and all were haploinsufficient for TBX1, except 
for one atypical B- D deletion (Table 1). We obtained informed 
written consent from primary caregivers and participants. The 
National Health Service Wales Research Ethics Committee ap-
proved our protocols.
2.2 | Screening for lifetime history of 
epilepsy, seizures, and seizurelike symptoms
We used the validated Epilepsy Screening Questionnaire 
(ESQ; Ottman et al,25 Table 2) to screen for an epilepsy di-
agnosis (Item 9), seizures (Items 1 and 2) and seizurelike 
symptoms (behaviors that may reflect unrecognized epilep-
tic seizures, Items 3- 8). We created two dichotomous sum-
mary variables: “any positive,” a positive response (“yes” or 
“possibly”) to at least one item; and “any positive excluding 
epilepsy,” a positive response to any of Item 1 to Item 8 in 
those without epilepsy. The ESQ was originally self- report25; 
however, we asked the primary caregiver to complete it in 
all cases, given the age and presence of mild- moderate ID 
in our 22q11.2DS sample.3 In the Ottman et al25 validation 
study, participants were only asked about afebrile seizures 
and seizurelike symptoms if they didn't have epilepsy. We 
asked all items, to probe for unrecognized seizures in epi-
lepsy patients.
2.3 | Second stage of assessment of epileptic 
seizures and epilepsy
To validate our screening findings, we conducted a second 
assessment in a subsample of 40 deletion carriers and 4 con-
trols with “any positive.”
A trained researcher interviewed the primary care-
giver about ESQ- reported events (for 37 deletion carriers 
and 4 controls), using an amended version of the validated 
Seizure Classification Interview (SCI), developed by Ottman 
et al.26,27 Diagnoses from the SCI show fair to excellent non-
chance agreement with neurologist diagnoses in studies of 
epilepsy patients (k = 0.54- 0.83).26 We used the interview 
to establish whether ESQ- reported events were epileptic sei-
zures. We therefore combined the “grand mal” and “small 
seizures” sections into an “unusual spell” section. In addi-
tion, we added a section on febrile seizures specifically. We 
undertook medical record reviews where available (11 dele-
tion carriers).
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We conducted prolonged ambulatory EEG with 28 dele-
tion carriers and 4 controls, with overnight  video- monitoring 
(22q11.2DS: mean recording length 13:41:16, SD 04:59:40, 
range 3:30:00- 21:03:06, controls: mean 11:14:38, SD 05:14:36, 
range 03:25:00- 14:25:23). Recordings were performed using a 
64- channel Hydrocel Geodesic Sensor Net (Electrical Geodesics 
Inc.) and a BE PLUS LTM amplifier (EB Neuro S.p.A.).
A consultant epileptologist and a consultant neurophys-
iologist reviewed the EEG traces, and participants had their 
epileptic seizures classified and epilepsy diagnosed by the 
epileptologist, according to International League Against 
Epilepsy (ILAE) criteria.28–30
2.4 | IQ and psychopathology
We derived the child's full- scale IQ (FSIQ), performance 
IQ (PIQ) and verbal IQ (VIQ) scores from the Wechsler 
Abbreviated Scale of Intelligence (WASI).31 ID was de-
fined as FSIQ <70. We conducted the Child and Adolescent 
Psychiatric Assessment interview (CAPA)32 with the pri-
mary caregiver to diagnose ADHD and anxiety disorder, 
according to Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision (DSM- IV- TR)33 
criteria. We screened for indicative ASD using the Social 
Communication Questionnaire,34 completed by the primary 
caregiver.
2.5 | Other neurodevelopmental problems
We screened for indicative developmental coordination dis-
order (DCD) using the Developmental Coordination Disorder 
Questionnaire (DCDQ),35,36 completed by the primary car-
egiver. Sleep disturbance was defined as a score of two on 
one item from the CAPA sleep section. Primary caregivers 
provided information on preterm birth, cardiovascular prob-
lems, recurrent infections, and lifetime medication use.
Sample sizes for the ESQ, IQ, psychopathology, and other 
neurodevelopmental problem datasets differed due to the 
child or parent not completing part/all of one or more mea-
sures. The primary caregiver was not available for the SCI for 
three deletion carriers who underwent EEG.
2.6 | Statistical analyses
Statistical analyses were conducted in R version 3.5.1 (https://
www.R-project.org/).
2.6.1 | Screening for lifetime history of 
epilepsy, seizures, and seizurelike symptoms
We used logistic regression analyses to measure associations 
between deletion status (22q11.2DS/control) and the “any 
positive” and “any positive excluding epilepsy” variables. 
Predictors were entered hierarchically: age first, then gender, 
then deletion status. We conducted a sensitivity analysis to 
explore whether preterm birth, cardiovascular problems, and 
lifetime history of psychotropic and/or antiepileptic medica-
tion use influenced our findings. We explored associations 
between deletion status and response to each ESQ item using 
χ2/Fisher's exact test. We conducted a logistic regression 
T A B L E  1  Descriptive statistics of the sample
%
Deletion etiology
De novo 77.8
Inherited 8.3
Unknown 13.9
Deletion type
~3 Mb A- D 75.9
~2 Mb A- C 0.9
~1.5 Mb A- B 6.5
Atypical ~1.5 Mb B- D 0.9
Unknown 15.8
Family ethnic background
European 85.2
Mixed 10.2
Non- European 1.9
Unknown 2.8
Highest parental qualificationa
Low (O- levels/GCSEs) 23.2
Middle (A- levels/highers/vocational training) 32.4
High (university degree and/or other higher 
postgraduate qualification)
32.4
Unknown 12.0
Family income
≤£19 999 22.2
£20 000- £39 999 24.1
£40 000- £59 999 21.3
≥£60 000 23.1
Unknown 9.3
Mean SD Range
Age
22q11.2DS 13.6 3.3 6.2- 20.5
Controls 13.1 3.2 6.3- 18.9
Male (%) Female (%)
Gender
22q11.2DS 62 (57.4) 46 (42.6)
Controls 30 (50) 30 (50)
GCSE, General Certificate of Secondary Education; 22q11.2DS, 22q11.2 dele-
tion syndrome.
aOf the parent completing the questionnaire. 
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exploring whether recurrent infections predicted febrile sei-
zures in deletion carriers.
2.6.2 | Second stage of assessment of 
epileptic seizures and epilepsy
For the “epilepsy diagnosis” and “any positive excluding 
epilepsy” ESQ variables, we calculated the percentage of 
deletion carriers who were diagnosed with epilepsy and epi-
leptic seizures by our epileptologist, respectively, as well as 
the rates of epileptiform discharges in these groups; no back-
ground abnormalities were observed. We also calculated the 
percentage of deletion carriers reported with febrile seizures 
(Item 1, Table 2) who had their report confirmed by our epi-
leptologist. For controls, we repeated these analyses with 
the “any positive excluding epilepsy” ESQ variable only (no 
controls had epileptic seizures or abnormal EEG findings).
We calculated the rate of different seizure etiologies in 
deletion carriers who were diagnosed with epileptic sei-
zures. We also explored characteristics of febrile and un-
provoked seizures (the most common seizure etiologies in 
our sample) such as the semiology (rates of generalized and 
focal seizures), median age at onset (months), median num-
ber, median length (seconds), and frequency (rates of four 
different categories; Table 4; eg, less than once a month).
2.6.3 | Association of the ESQ with 
neurodevelopmental problems in 22q11.2DS
In deletion carriers, we used logistic regression analyses to 
explore the associations of the “any positive” “any positive 
excluding epilepsy” and “febrile seizure” ESQ variables 
with IQ scores, ID, psychopathology, indicative DCD, and 
T A B L E  2  Rates of positive responses on each item of the Epilepsy Screening Questionnaire in young people with 22q11.2DS and their 
unaffected control siblings
Item
Positive response
χ2 OR P value22q11.2DS, n (%) Controls, n (%)
1. Did your son/daughter ever have a seizure or convulsion 
caused by a high fever?a
26 (24.3) 0 (0) 17 _ <0.001
2. Other than the seizures associated with high fevers, has 
your son/daughter ever had a seizure, convulsion, fit, or 
spell—under any circumstances?b
26 (24.1) 0 (0) 16.8 _ <0.001
3. Other than the seizures associated with high fevers, has 
your son/daughter ever had uncontrolled movements of part 
or all of his/her body such as twitching, jerking, shaking, or 
going limp?c
21 (19.8) 2 (3.3) 8.72 7.1 0.003
4. Other than the seizures associated with high fevers, has 
your son/daughter ever had an unexplained change in his/her 
mental state or level of awareness; or an episode of “spacing 
out” that he/she could not control?d
19 (17.8) 1 (1.7) 9.44 12.6 0.002
5. Does your son/daughter daydream or stare into space more 
than other children?
43 (40.2) 5 (8.3) 19 7.31 <0.001
6. Have you ever noticed him/her to have any unusual body 
movements when exposed to strobe lights, video games, 
flickering lights, or sun glare?
3 (2.8) 0 (0) Fisher’s 
exact test
_ 0.553
7. Shortly after waking up, either in the morning or after a 
nap, have you ever noticed your son/daughter have uncon-
trollable jerking or clumsiness, such as dropping things or 
things suddenly flying from his/her hands?
10 (9.3) 0 (0) Fisher’s 
exact test
_ 0.014
8. Has your son/daughter ever had any other type of repeated 
unusual spells?
7 (6.5) 0 (0) Fisher’s 
exact test
_ 0.051
9. Has your son/daughter ever been diagnosed with a seizure 
disorder or epilepsy?
12 (11.1) 0 (0) Fisher’s 
exact test
_ 0.004
22q11.2DS, 22q11.2 deletion syndrome; OR, odds ratio.
aData available for 107 probands and 59 control siblings. 
bData available for 59 control siblings. 
cData available for 106 probands. 
dData available for 107 probands. 
   | 823EATON ET Al.
sleep disturbance. Predictors were entered hierarchically, 
age first, then gender, and finally the neurodevelopmental 
variable. We compared FSIQ, VIQ, and PIQ scores and rates 
of ID, psychopathology, indicative DCD, and sleep distur-
bance between deletion carriers and controls using t tests 
and χ2 tests.
3 |  RESULTS
Table 1 displays descriptive statistics about our sample.
3.1 | Screening for lifetime history of 
epilepsy, seizures, and seizurelike symptoms
Table 2 shows the rates of positive responses on each ESQ 
item. Sixty- nine of 108 (63.9%) deletion carriers had “any 
positive” compared to 13.3% (8/60) of controls (b = 2.49, 
z = 5.67, odds ratio [OR] 12, P < 0.001). Of deletion car-
riers, 11.1% (12/108) had an epilepsy diagnosis, yet when 
excluding these cases 59.4% (57/96) had “any positive 
excluding epilepsy” compared to 13.3% (8/60) of con-
trols (b = 2.27, z = 5.15, OR 9.66, P < 0.001). Around a 
quarter of deletion carriers had febrile seizures (controls 
0%, P < 0.001, Table 2). Positive responses were signifi-
cantly more common in deletion carriers than in controls 
for four of the seizurelike symptom items (Items 3, 4, 5, 
and 7 in Table 2). Age and gender did not influence these 
relationships.
Nineteen of 108 (17.6%) deletion carriers had a lifetime 
history of psychotropic and/or antiepileptic medication use. 
Fourteen of 103 cases (13.6%) and 4.3% (2/46) of controls 
were born prematurely; 64.8% (68/105) of cases and 1.8% 
(1/59) of controls had cardiovascular problems. These co-
morbidities did not influence our findings.
The majority of deletion carriers had recurrent infections 
(68.9%, 73/106, controls 10.9%, 6/55; P < 0.001). Deletion 
carriers with recurrent infections were not more likely to re-
port febrile seizures, however (b = 0.78, z = 1.41, P = 0.157).
3.2 | Second stage of assessment of epileptic 
seizures and epilepsy
Deletion carriers in the second assessment did not differ sig-
nificantly from those who did not take part with respect to 
their FSIQ score, rate of psychopathology, or highest level of 
parental education (P > 0.05 in all cases), although they were 
significantly older (14.4 years vs 12.17 years, P = 0.005). 
The results from the second assessment are shown in Table 3. 
For most deletion carriers reported as having epilepsy, whose 
caregiver was subsequently interviewed, the diagnosis was 
confirmed (5/6, 83%). The remaining individual had an iso-
lated unprovoked generalized tonic–clonic seizure (GTCS). 
One deletion carrier was reported as having epilepsy based on 
a history of what a pediatrician had described as “petit mal” 
seizures. We reclassified these as focal nonmotor seizures 
with impaired awareness, in the context of right- hemisphere 
polymicrogyria (reported during the SCI). For this participant, 
we further diagnosed a report of repeated left- sided numbness 
and clumsiness in the morning as focal motor (postictal) sei-
zures, thereby identifying an additional seizure type.
Just over half of deletion carriers with “any positive ex-
cluding epilepsy,” whose caregiver was subsequently in-
terviewed, were diagnosed with epileptic seizures (16/31; 
51.6%). In two, the diagnosis was “possible” nonmotor ab-
sence seizures (based on a history of daydreaming spells). 
Their caregivers reported that they had not seen a clinician 
for these events. Of interest, the EEG for one of these two 
displayed short bursts of generalized and left hemisphere 
spike- and- slow- wave discharges, occurring during sleep and 
shortly after awakening (Figure S1). A further 2 of the 16 
individuals also met criteria for epilepsy. The primary care-
giver for one described a history of repeated unprovoked 
GTCS in the SCI, but no epilepsy diagnosis. However, a child 
development clinic letter listed epilepsy as a diagnosis. For 
the other individual, we diagnosed a history of repeated “star-
ing spells” as nonmotor absence seizures. Medical records 
were unavailable, but the primary caregiver reported that 
a pediatrician had previously described these as “possible 
T A B L E  3  Results from the second stage of assessment in young people with 22q11.2DS and control siblings
ESQ variable
n screening positive/
total n (%)
Interview 
completed? (%)
Diagnosis confirmed by 
epileptologist? (%)
EEG com-
pleted? (%)
Epileptiform 
discharges? (%)
22q11.2DS
ESQ: epilepsy 
diagnosis
12/108 (11.1) 6/12 (50) 5/6 (83.3) 2/12 (16.7) 0/2 (0)
ESQ: “any positive 
excluding epilepsy”
57/96 (59.4) 31/57 (54.4) 16/31 (51.6) 26/57 (45.6) 3/26 (11.5)
Controls
ESQ: “any positive 
excluding epilepsy”
8/60 (13.3) 4/8 (50) 0/4 (0) 4/8 (50) 0/4 (0)
22q11.2 DS, 22q11.2 deletion syndrome; EEG, electroencephalography; ESQ, Epilepsy Screening Questionnaire.
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absence seizures” and that further assessments had not been 
conducted as these events had stopped. Of interest, this child 
showed brief generalized spike- and- slow- wave epileptiform 
discharges shortly after awakening. The remaining deletion 
carriers (15/31) were diagnosed with nonepileptic events (eg, 
daydreaming), although one showed brief generalized, left 
and right hemisphere spike- and- slow- wave discharges during 
sleep. Eighty percent of these individuals (12/15) were only 
reported to have seizurelike symptoms on the ESQ.
Most deletion carriers with ESQ- reported febrile sei-
zures, whose caregiver was subsequently interviewed, were 
diagnosed with febrile seizures (16/17, 94%). The remaining 
individual had fever- related delirium. All controls reported 
as having “any positive excluding epilepsy” were diagnosed 
with nonepileptic events.
Table 4 shows salient characteristics of epileptic seizures 
in deletion carriers. Febrile and unprovoked epileptic sei-
zures were the most common seizure etiologies (77.3% and 
45.5%, respectively). All febrile seizures were convulsive, 
with a median estimated length of 2.5 minutes. On average, 
febrile seizures began within the first 2 years of life and were 
recurrent. Unprovoked seizures were not linked to a struc-
tural etiology in 60% of deletion carriers. In the remaining 
40%, unprovoked seizures were seen in children with struc-
tural brain abnormalities or potential acquired causes; right 
hemisphere polymicrogyria, perinatal subdural hematoma, 
possible postpneumococcal meningitis (SCI- report only), 
and neonatal hypoxic- ischemic encephalopathy (SCI- report 
and medical records). Unprovoked seizures were mostly gen-
eralized, lasted for ~2 minutes on average, and onset within 
the first 3 years of life. Thirty percent experienced daily 
unprovoked seizures at their most frequent. These three in-
dividuals had focal motor seizures with postictal left- sided 
numbness upon awakening; “possible” nonmotor absence 
seizures; and GTCS with nonmotor absence seizures.
Other seizure etiologies not shown in Table 4 include hy-
pocalcemia (9.1%, 2/22, GTCS in both cases), cardiac sur-
gery (4.5%, 1/22, focal motor seizure), and hypoxic- ischemic 
encephalopathy (4.5%, 1/22, focal motor seizure, possibly to 
bilateral tonic– clonic).
3.3 | Association of the ESQ with 
neurodevelopmental problems in 22q11.2DS
3.3.1 | IQ and ID
The mean FSIQ, PIQ, and VIQ of deletion carriers were 
significantly lower than in controls (Table S1). One dele-
tion carrier had a higher- than- average FSIQ (117), whereas 
12.1% (12/99) and 40.4% (40/99) were in the average (86- 
115) and borderline ranges (71- 85), respectively; 41.4% 
(41/99) had mild ID (55- 70) and 5.1% had (5/99) moderate 
ID (IQ < 55). By contrast, 94.5% (52/55) of control siblings TA
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had an average- or- higher FSIQ and only 3 (5.5%) had a bor-
derline FSIQ. “Any positive” was more common in deletion 
carriers with a lower PIQ (P = 0.018, Table 5). This relation-
ship was not observed for “any positive excluding epilepsy” 
(P = 0.060) or febrile seizures (P = 0.105). None of the ESQ 
variables were predicted by FSIQ, VIQ, or ID. Age and gen-
der did not influence our findings.
3.3.2 | Psychopathology, sleep 
disturbance, and motor coordination problems
We found higher rates of psychopathology, sleep distur-
bance, and indicative DCD in cases relative to controls 
(Table S1). Deletion carriers with ADHD were around three 
times more likely to have “any positive” and those with in-
dicative ASD and DCD were around four times more likely 
(Table 5). The associations with indicative ASD and DCD 
held for “any positive excluding epilepsy” (P = 0.018 and 
P = 0.026, respectively), although the relationship with 
ADHD disappeared (P = 0.163). None of these relation-
ships held for febrile seizures. None of the ESQ variables 
were predicted by psychiatric disorders as a group, anxiety 
disorder, or sleep disturbance. Age and gender did not influ-
ence our findings.
Overlap between “any positive” indicative DCD, ADHD, 
and indicative ASD was common in 22q11.2DS (Figure 1). 
Of those with indicative DCD, 58.2% (46/79) had “any pos-
itive,” as did 70.3% (26/37) with indicative ASD and 66.7% 
(20/30) with ADHD; 10.6% (10/94) screened positive in all 
four domains.
4 |  DISCUSSION
We showed that 11.1% of deletion carriers screened posi-
tive for an epilepsy diagnosis, a rate that falls within the 
wide- ranging prevalence estimates from previous stud-
ies (4.4%- 36.8%9,13–15,17,18). Over half of deletion carriers 
were, however, reported to have seizures or seizurelike 
symptoms without a diagnosis. In addition, 24.1% were re-
ported to have febrile seizures. Results from a second stage 
of assessment (interview, prolonged ambulatory EEG, 
medical records, epileptologist review) indicated that rates 
T A B L E  5  IQ scores and rates of neurodevelopmental problems for young people with 22q11.2DS on the “any positive” summary variable
Measure n
Any positive
b z OR P  valueNo (SD) Yes (SD)
FSIQ 99 73.94 (13.31) 70.35 (11.15) −0.02 −1.39 0.98 0.163
PIQ 99 78.49 (14.05) 72.31 (10.94) −0.04 −2.36 0.96 0.018
VIQ 100 73.98 (13.25) 72.38 (12.20) −0.01 −0.59 1 0.556
Neurodevelopmental 
problem
n 
affected/total 
n
Any positive
b z OR P valueNo (%) Yes (%)
ID 42/99 17 (36.2) 25 (48.1) 0.44 1.02 1.55 0.921
Any psychiatric 
disorder
53/108 33 (56.9) 20 (40) 0.76 1.87 2.13 0.062
ADHD 30/106 10 (20) 20 (35.7) 1.19 2.32 3.28 0.021
Any anxiety disorder 31/108 11 (22.0) 20 (34.5) 0.6 1.36 1.83 0.175
Any sleep problem 63/107 31 (62) 32 (56.1) −0.24 −0.59 0.79 0.558
Indicative ASD 37/90 11 (25.6) 26 (55.3) 1.35 2.86 3.86 0.004
Indicative DCD 79/95 33 (73.3) 46 (92.0) 1.52 2.31 4.56 0.021
22q11.2DS, 22q11.2 deletion syndrome; SD, standard deviation; ADHD, attention- deficit/hyperactivity disorder; ASD, autism spectrum disorder; DCD, developmental 
coordination disorder; FSIQ, full- scale IQ, ID, intellectual disability; PIQ, performance IQ, VIQ, verbal IQ.
F I G U R E  1  Overlap of “any positive” on the Epilepsy Screening 
Questionnaire, indicative DCD, ADHD, and indicative ASD in 
22q11.2DS. DCD, developmental coordination disorder, ADHD, 
attention- deficit/hyperactivity disorder, ASD, autism spectrum 
disorder; DCD, developmental coordination disorder
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of questionnaire- reported epilepsy and febrile seizures 
were accurate and highlighted that in some deletion carri-
ers, epileptic seizures may not be recognized during routine 
clinical care, and an epilepsy diagnosis may be overlooked. 
Deletion carriers who took part in the second assessment 
were older than those who did not, because this second as-
sessment was conducted as part of a longitudinal study of 
development in young people with 22q11.2DS (Chawner 
et al37). Deletion carriers who screened positive on the 
epilepsy questionnaire had higher rates of ADHD, indica-
tive ASD, indicative DCD, and a lower PIQ. These asso-
ciations remained significant when cases with an epilepsy 
diagnosis were excluded, with the exception of ADHD, but 
none remained significant for febrile seizures. We propose 
that risk for epileptic seizures in deletion carriers may be 
symptomatic of underlying aberrant synaptic plasticity and 
an imbalance in neuronal excitation- inhibition, also giving 
rise to impaired cognition, psychopathology, and motor co-
ordination problems.
4.1 | Epilepsy, seizures, and seizurelike 
symptoms in young people with 22q11.2DS
We observed an ~60% rate of ESQ- reported seizures and 
seizurelike symptoms in deletion carriers, after excluding 
reported epilepsy cases. These events were more prevalent 
than in controls and showed many of the same associations 
with poorer neurodevelopmental outcomes as epilepsy. Our 
second assessment suggested that half of deletion carriers 
reported with these events may have had “true” epileptic 
seizures, mainly febrile and/or unprovoked. Crucially, this 
assessment also suggested that epileptic seizures may not 
be recognized during routine clinical care in some deletion 
carriers. We also newly diagnosed epilepsy in an individ-
ual with a clinical history of suspected seizures (nonmotor 
absences). Our findings are limited somewhat by the “pos-
sible” seizure attribution for two deletion carriers, due to 
remote epileptologist assessment. The ESQ may not detect 
some deletion carriers with clinically diagnosed epilepsy, 
as we found for one participant when cross- referencing 
with medical records. Ultimately, prospective and sys-
tematic study of all ESQ- reported seizures and seizurelike 
symptoms, incorporating direct epileptologist assessment, 
will best address the extent to which epileptic seizures and 
epilepsy are overlooked in 22q11.2DS.
4.1.1 | Febrile seizures
Our rate of reported febrile seizures in deletion carriers 
(24.1%) was higher than previous estimates (2%- 6%).12,13,15 
This was not explained by the recurrent infections in this syn-
drome and suggests a reduced seizure threshold, supporting 
previous findings in adult deletion carriers with psychotropic 
and hypocalcemia- induced seizures.13
Febrile seizures in deletion carriers resembled the “simple” 
phenotype, considered to be relatively benign.38 Supporting 
this, ESQ- reported febrile seizures did not associate with 
poorer neurodevelopmental outcomes. Future longitudinal 
studies may better characterize the relationship of febrile sei-
zures with neurodevelopmental trajectories in 22q11.2DS.
4.1.2 | Unprovoked seizures
The median age at onset of unprovoked seizures (33 months) 
and febrile seizures (14 months) suggests that deletion car-
riers are at risk for epileptic seizures from early in life. 
Unprovoked seizures were occurring once a day or more 
when at their most frequent in 30% of deletion carriers.
4.2 | Association of the ESQ with 
neurodevelopmental problems in 22q11.2DS
The associations of ESQ- reported epilepsy, seizures, and 
seizurelike symptoms with impaired cognition, psychopa-
thology, and motor coordination problems in deletion car-
riers replicate findings from the general population39–41 and 
suggest shared neurobiologic risk pathways. One pathway 
could be aberrant synaptic plasticity and a subsequent im-
balance in neuronal excitation- inhibition. This mechanism 
associates with both epilepsy and autism.42 In a mouse 
model of ASD, aberrant synaptic plasticity was implicated 
in motor learning deficits via impaired cerebellar long- term 
depression response and synaptic pruning.43 Synaptic plas-
ticity in the prefrontal cortex is important in adolescent de-
velopment of executive function, a behavioral impairment 
in ADHD.44 Impaired hippocampal synaptic plasticity 
shows links with memory deficits.45,46 Aberrant synaptic 
plasticity is also implicated in the emergence of the sen-
sory, cognitive, motor, and psychotic features that charac-
terize schizophrenia,47 for which 22q11.2DS confers risk 
(22%).7 Mouse models of 22q11.2DS have demonstrated 
aberrant synaptic plasticity. For example, hemizygosity for 
the microRNA biogenesis gene Dgcr8 leads to enhanced 
short- and long- term synaptic plasticity within hippocam-
pal CA3- CA1 synapses, coinciding with spatial memory 
deficits, as well as enhanced short- term depression in the 
prefrontal cortex. Mice that are haploinsufficient for the 
mitochondrial function gene Mrpl40 also show abnormal 
short- term potentiation within the hippocampus and co- 
occurring working memory deficits. The aberrant synaptic 
plasticity in these mouse models is mediated by dysregu-
lation of presynaptic calcium levels and neurotransmitter 
release (eg, enhanced glutamate activity).45,46,48
Epileptic seizures may also cause neurobiologic changes 
resulting in impaired cognition and ASD- related behaviors, 
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notably within the hippocampus,42 and may alter cerebral 
functional organization of motor control.49 Paroxysmal epi-
leptic activity associates with poorer performance on atten-
tion tests.50 Early life seizures may therefore have deleterious 
effects on vulnerable neural networks in 22q11.2DS, for ex-
ample, within hippocampal and prefrontal regions,18,46,48 ex-
acerbating impaired cognition, psychopathology, and motor 
coordination problems. Future longitudinal designs are war-
ranted to assess this hypothesis.
4.3 | Limitations of the Epilepsy Screen 
Questionnaire, and implications for 
our findings
The ESQ has high sensitivity for identifying epilepsy pa-
tients (96%) and a low false- positive rate among seizure- free 
individuals (7%). However, the estimated positive predic-
tive value (PPV, the proportion of screen- positive individu-
als who have epilepsy) in the general population is low 
(23%, possible range 0%- 100%25) reflecting the low preva-
lence of epilepsy (~1%39). The estimated rate of epilepsy 
in 22q11.2DS is higher (4.4%- 36.8%9,13–15,17,18); however, 
false positives can be expected to occur as a consequence of 
the complex phenotypic presentation. The results of our sec-
ond assessment do suggest, however, that most of the ESQ- 
reported epilepsy diagnoses were genuine, and that half of 
deletion carriers reported with seizures or seizurelike symp-
toms may have had “true” epileptic seizures. Future stud-
ies replicating our method should ensure that all individuals 
with “any positive” take part in the second stage to establish 
the PPV of the ESQ for epileptic seizures in 22q11.2DS.
4.4 | Clinical implications
Our work reinforces that not only are children with 
22q11.2DS at risk of acute symptomatic seizures and 
epilepsy during the early years of life, but that in some, 
epileptic seizures may not be recognized during routine 
clinical care and an epilepsy diagnosis may be overlooked. 
We recommend a high- index of suspicion for epileptic 
seizures in 22q11.2DS, with epileptologist consultation 
and video- EEG for uncertain cases. Early intervention 
for epileptic seizures is important given the associations 
with poorer neurodevelopmental outcomes. A micro- 
chromosomal array should be considered to screen for 
22q11.2DS in children presenting with epileptic seizures 
and congenital heart disease, palatal abnormalities, hy-
pocalcemia, ID, psychopathology, or motor coordination 
deficits.
In conclusion, we demonstrated that ~60% of young people 
with 22q11.2DS screen positive for seizures and seizurelike 
symptoms in the absence of an epilepsy diagnosis. Systematic 
investigation of a subsample showed that epileptic seizures 
may not be recognized during routine clinical care and that an 
epilepsy diagnosis may be overlooked. Risk for epileptic sei-
zures in 22q11.2DS may be symptomatic of aberrant synaptic 
plasticity and an imbalance in neuronal excitation- inhibition, 
also leading to cognitive impairment, psychopathology, and 
motor coordination problems. We observed a high rate of fe-
brile seizures (24.1%), which provides further evidence for 
a reduced seizure threshold in 22q11.2DS. Highlighting the 
prevalence of epileptic seizures and epilepsy and their rela-
tionship with neurodevelopment in 22q11.2DS could allow 
focused intervention by clinicians, ultimately improving out-
comes in this syndrome.
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